510(k)

K163172: HemoDraw Plus Closed Blood Sampling System with LogiCal Transducer Kit, HemoDraw Plus Closed Blood Sampling System with Transtar Transducer Kit

FDA 510(k) · Smiths Medical Asd, Inc. · decided May 24, 2017

Key facts

510(k) number K163172
Device name HemoDraw Plus Closed Blood Sampling System with LogiCal Transducer Kit, HemoDraw Plus Closed Blood Sampling System with Transtar Transducer Kit
Applicant Smiths Medical Asd, Inc.
Product code DRS
Date received Nov 14, 2016
Decision date May 24, 2017
Decision Substantially equivalent (SESE)
Submission type Traditional
Review panel Cardiovascular
Medical specialty Cardiovascular

At a glance

  • None MAUDE adverse event reports
  • None Recall events
  • 10–99 UDI device identifiers (GUDID)
  • 1–9 Predicate devices cited
  • 1–9 Later submissions citing this device
  • 100–999 510(k)s with this product code
  • Yes 510(k) summary on file
  • No 510(k) statement on file
  • Not listed On the FDA AI-enabled device list

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

Reading a 510(k)

Decision
SESE means the FDA found the device substantially equivalent to its predicate, so it may be marketed in the United States.
Predicates
Each clearance cites one or more legally marketed devices; the chain of predicates shows where a technology came from.
Product code
The three-letter code sets the device type, class and regulation, and groups competing clearances.
Summary or statement
Applicants file either a 510(k) summary of the safety and effectiveness information or a statement that it is available on request.

About 510(k) premarket notifications

A 510(k) is a premarket submission made to the FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device.

Source: U.S. Food and Drug Administration (FDA), 510(k) Premarket Notification database · Source date:

Browse all 510(k) premarket notifications